Laboratory Corp. of America Holdings (LH) again extended its $84 million cash tender offer for Orchid Cellmark Inc. (ORCH), as the medical-testing services provider continues to work through an information request from the Federal Trade Commission.

In April, LabCorp said it would acquire DNA-testing services company Orchid in a bid to strengthen its presence in the U.S. and give it a foothold in Britain. It has twice previously extended its tender offer for the company after receiving in May a request for more information from the FTC.

On Monday, LabCorp said it is continuing to cooperate with the FTC. The offer is now set to expire Aug. 12. LabCorp said as of 5 p.m. EDT Friday, stockholders had validly tendered roughly 87% of Orchid's outstanding shares.

In its most recent results, LabCorp reported first-quarter earnings fell 4.2% on higher costs, though core results beat analyst expectations.

LabCorp shares closed at $95.73 Friday and were inactive in premarket trade. The stock is up 8.9% since the start of the year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Orchid Cellmark (NASDAQ:ORCH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Orchid Cellmark.
Orchid Cellmark (NASDAQ:ORCH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Orchid Cellmark.